Pharmaceutical combined preparation containing claudin18.2 pg car-t preparation and pg antibody preparation and use thereof

Through the combination of molecular switch-regulated chimeric antigen receptor cells and recombinant anti-close junction 18.2 monoclonal antibody, the problems of CAR-T cell activity control and drug combination stability were solved, and efficient killing of Claudin18.2-positive tumors were achieved. and safe treatment.

WO2024240200A1PCT designated stage expired Publication Date: 2024-11-28INNOVENT CELLS PHARM (SU ZHOU) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094824
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

In the prior art, the lack of drug combinations containing PG CAR-T cells and PG antibodies targeting Claudin18.2 can ensure long-term stable storage of drug combinations, and there is a problem of lack of control of CAR-T cell activity and normal tissue recognition killing. Causes toxic side effects.

Method used

By developing molecular switch-regulated chimeric antigen receptor cells, using Pro329Gly mutant antibody as molecular switch, combining recombinant anti-close 18.2 monoclonal antibody, optimize the prescription of chimeric antigen receptor T cells and antibody preparations to improve the stability of drug combinations and the ability to specifically kill tumor cells.

Benefits of technology

The stability and safety of CAR-T cells and recombinant anti-clone 18.2 monoclonal antibodies were achieved, reducing the toxic side effects, and ensuring effective killing of tumor cells and cytokine release.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024094824-FTAPPB-I100001
    Figure PCTCN2024094824-FTAPPB-I100001
  • Figure PCTCN2024094824-FTAPPB-I100002
    Figure PCTCN2024094824-FTAPPB-I100002
  • Figure PCTCN2024094824-FTAPPB-I100003
    Figure PCTCN2024094824-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a pharmaceutical combined preparation containing a Claudin18.2PG CAR-T preparation and a PG antibody preparation, and the use thereof. Further provided is a pharmaceutical combined preparation, which contains a preparation A and a preparation B, wherein the preparation A contains a therapeutically effective amount of an immune effector cell expressing a molecular switch-regulated chimeric antigen receptor (CAR) polypeptide and a pharmaceutical excipient I, and the preparation B contains a therapeutically effective amount of an antibody or an antigen-binding fragment containing a P329G mutation and specifically binding to a CLDN18.2 molecule, and a pharmaceutical excipient II. A preparation formulation with stable CAR-T cells and a preparation formulation with a stable recombinant anti-Claudin 18.2 monoclonal antibody are determined by means of screening and optimization. The formulation of the pharmaceutical combined preparation can ensure the long-term stable storage of the pharmaceutical combination of the present invention, and has the advantages of simple components and usability.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical combination preparations comprising Claudin18.2 PG CAR-T preparations and PG antibody preparations and uses thereof

[0001] Priority and related applications

[0002] The present invention claims priority to Chinese patent application No. 202310593745.2 filed on May 24, 2023, entitled “Drug combination preparation comprising Claudin18.2 PG CAR-T preparation and PG antibody preparation and use thereof”, the entire contents of which, including the appendix, are incorporated herein by reference. Technical Field

[0003] The present invention relates to a pharmaceutical combination preparation comprising a Claudin18.2 PG CAR-T preparation and a PG antibody preparation and uses thereof, belonging to the technical field of antibody drugs. Background Art

[0004] Claudin is a key component of the tight junction complex, which plays a crucial role in human life. On one hand, tight junctions function as a barrier, selecting substances based on size and charge, thereby regulating paracellular transport. For example, cerebral endothelial cells use this barrier to prevent mixing of blood and extracellular fluid. On the other hand, tight junctions also function as fences, maintaining cell polarity by regulating the free diffusion of substances such as lipids and proteins between the apical and basolateral membranes.

[0005] Claudin18.2, a member of the Claudin protein family, is a highly tissue-specific protein, expressed only in differentiated epithelial cells of the gastric mucosa under normal physiological conditions. Studies have found that Claudin18.2 is highly expressed in many tumors, including gastric cancer, pancreatic cancer, esophageal adenocarcinoma, and colorectal adenocarcinoma. This restricted expression in normal tissues and specific high expression in tumors makes Claudin18.2 an ideal target for researchers developing immunotherapies for solid tumors.

[0006] As a new type of genetically engineered, highly efficient, and precisely targeted tumor cell immunotherapy drug, CAR-T cells have demonstrated great therapeutic potential in the treatment of hematological tumors. Multiple products have been approved for marketing at home and abroad, but breakthroughs are urgently needed in the treatment of solid tumors.

[0007] Traditional chimeric antigen receptor T cells (CAR-T) directly target surface antigens on tumor cells through chimeric antigen receptor (CAR) molecules on T cells, thereby achieving the purpose of identifying and killing tumors. The N-terminus of the chimeric antigen receptor contains an antigen-binding domain that recognizes the antigen, for example, a single-chain antibody fragment (scFv) targeting the antigen. The drawback of traditional chimeric antigen receptor T cells is that the activity of the CAR-T cells is poorly controlled. As long as the antigen-positive cells targeted by the CAR-T cells are present, the CAR-T cells will continue to recognize and kill these antigen-positive cells.

[0008] Since most tumor antigens targeted by CAR-T cells are not tumor-specific, in addition to being expressed on tumor cells, these tumor antigens are often also expressed at low levels in many normal tissues, especially important tissues and organs. The recognition and killing of these normal tissues by CAR-T cells leads to "on-target / off tumor" toxicity, which may cause serious toxic side effects.

[0009] Drug stability is one of the important indicators to ensure the effectiveness and safety of drugs. Obtaining a formulation formula that gives drugs good stability is a key condition for maintaining the safety and effectiveness of drugs during their shelf life. In the prior art, there is a lack of formulation formulas for drug combinations containing PG CAR-T cells targeting Claudin18.2 and PG antibodies that can ensure long-term stable storage of the drug combination (e.g., 24 months) and have simple ingredients and ease of use.

[0010] Summary of the Invention

[0011] Problems to be solved by the invention

[0012] In response to the problems existing in the prior art, the present invention provides a pharmaceutical combination preparation comprising a Claudin18.2 PG CAR-T preparation and a PG antibody preparation and uses thereof.

[0013] Solutions for solving problems

[0014] In view of the problems existing in the above-mentioned prior art, the inventors have conducted in-depth research. Through research, the inventors have developed a group of "molecular switch" regulated chimeric antigen receptor cells, by using Pro329Gly (antibody Fc segment according to EU numbering, proline 329 is mutated to glycine, abbreviated as P329G or PG) mutant antibodies as "molecular switch" or adaptors, such CAR molecules are constructed, which can specifically bind to antibodies containing P329G mutant Fc domains but not antibodies not containing P329G mutant Fc domains (also referred to herein as "wild-type antibodies"), thereby, by combining immune effector cells (e.g., T cells) expressing the CAR with recombinant anti-tight junction protein 18.2 (Claudin 18.2) monoclonal antibodies as "molecular switches", for the treatment of diseases associated with CLDN18.2, such as cancers expressing or overexpressing CLDN 18.2, such as CLDN18.2-positive solid tumors.

[0015] On this basis, based on the platform experience, the inventors conducted forced tests at room temperature (22-26°C) and liquid nitrogen vapor phase (≤-150°C) storage stability experiments to investigate the effects of different excipient contents on the viability and phenotype of chimeric antigen receptor cells, and optimized and screened out formulations that were beneficial to the stability of chimeric antigen receptor T cells. The main test items during the research process included: cell viability, cell clumping rate, CD3 + CAR + In addition, the effects of different excipients on the stability of recombinant anti-Claudin 18.2 monoclonal antibodies were investigated through high-temperature forced experiments, accelerated experiments, long-term experiments, oscillation, freeze-thaw, and light stability experiments. The formulations that are beneficial to the recombinant anti-Claudin 18.2 monoclonal antibodies were optimized and screened. The main test items during this study included: appearance, pH value, antibody protein content, polysorbate 80 content, purity, charge variants, and biological activity.

[0016] That is, the inventors studied the types and addition ratios of various excipients in a pharmaceutical combination preparation comprising Claudin18.2 PG CAR-T cells and PG antibodies, and screened out formulations that are beneficial to the stabilization of chimeric antigen receptor T cells and formulations that are beneficial to the stabilization of recombinant anti-cleavage protein 18.2 (Claudin 18.2) monoclonal antibodies, thereby completing the present invention.

[0017] The first aspect of the present invention provides a pharmaceutical combination preparation comprising preparation A and preparation B;

[0018] Wherein, the preparation A comprises: a therapeutically effective amount of immune effector cells expressing a molecular switch-regulated chimeric antigen receptor (CAR) polypeptide and a pharmaceutical excipient I,

[0019] The pharmaceutical excipient I comprises: compound electrolyte injection, human serum albumin and CS10; Preferably, the compound electrolyte injection is Bomeili A compound electrolyte injection;

[0020] The preparation B comprises: a therapeutically effective amount of an antibody or antigen-binding fragment comprising the P329G mutation that specifically binds to the CLDN18.2 molecule and a pharmaceutical excipient II,

[0021] The P329G mutated antibody that specifically binds to the CLDN18.2 molecule comprises a mutated Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G), and the Fcγ receptor binding of the mutated Fc domain is reduced compared to the Fcγ receptor binding of the unmutated parent antibody Fc domain;

[0022] The pharmaceutical excipient II comprises: a pH regulator, an osmotic pressure regulator, a metal chelating agent and a surfactant;

[0023] In some preferred embodiments, the pH regulator is histidine and / or histidine hydrochloride, the osmotic pressure regulator is arginine hydrochloride and / or sorbitol, the surfactant is polysorbate 80, and the metal chelator is disodium edetate.

[0024] In some embodiments, the pharmaceutical combination preparation of the first aspect of the present invention, wherein the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide comprises:

[0025] (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that is capable of specifically binding to the Fc domain of an antibody comprising the P329G mutation but is unable to specifically bind to the Fc domain of an unmutated parent antibody:

[0026] (i) a heavy chain variable region comprising a

[0027] (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 13);

[0028] (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 14); and

[0029] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 15); and

[0030] (ii) a light chain variable region comprising a

[0031] (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 16);

[0032] (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 17); and

[0033] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 18);

[0034] Preferably, the (i) heavy chain variable region comprises the sequence of SEQ ID NO: 2, and (ii) light chain variable region comprises the sequence of SEQ ID NO: 3;

[0035] (2) a hinge region / spacer selected from the sequence shown in SEQ ID NO: 4 or SEQ ID NO: 5;

[0036] (3) a transmembrane region (TM), which is the CD8 transmembrane domain shown in SEQ ID NO: 6;

[0037] (4) a costimulatory signaling domain (CSD), which is the 4-1BB costimulatory domain shown in SEQ ID NO: 7;

[0038] (5) a stimulatory signaling domain (SSD), which is the CD3ζ signaling domain shown in SEQ ID NO: 8;

[0039] (6) a signal peptide sequence, which is the signal peptide sequence shown in SEQ ID NO: 1;

[0040] Preferably, the molecular switch-regulated CAR polypeptide has the amino acid sequence shown in SEQ ID NO: 9, and the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide comprises the nucleotide sequence shown in SEQ ID NO: 10;

[0041] The immune effector cells expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide are T cells; preferably, the T cells are autologous T cells or allogeneic T cells; more preferably, the immune effector cells are prepared by isolating T cells from human PBMCs;

[0042] Most preferably, the immune effector cell expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide is a HuR968B CAR-T cell.

[0043] In some embodiments, the pharmaceutical combination preparation of the first aspect of the present invention, wherein the immune effector cells expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide have a cell density of 1E6 cells / mL to 1E8 cells / mL in the preparation A;

[0044] The contents of the components in the pharmaceutical excipient I in the preparation A are: compound electrolyte injection 10.5% to 50.5% (v / v), human serum albumin 14.5% to 24.5% (v / v), CS10 50%~70% (v / v);

[0045] Preferably, the contents of the components in the pharmaceutical excipient I in the preparation A are CS10 50.0% (v / v), compound electrolyte injection 30.5% (v / v), human serum albumin 19.5%;

[0046] More preferably, the compound electrolyte injection is Bomeili A compound electrolyte injection.

[0047] In some embodiments, the pharmaceutical combination preparation of the first aspect of the present invention, wherein the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 represented by the amino acid sequence SYVMS (SEQ ID NO: 19) according to Kabat numbering; a CDR H2 represented by the amino acid sequence TISHSGGSTYYADSVKG (SEQ ID NO: 20); and a CDR H3 represented by the amino acid sequence DAPYYDILTGYRY (SEQ ID NO: 21); the light chain variable region comprises a CDR L1 represented by the amino acid sequence RASQSISSWLA (SEQ ID NO: 22) according to Kabat numbering; a CDR L2 represented by the amino acid sequence KASSLES (SEQ ID NO: 23); and a CDR L3 represented by the amino acid sequence QQYNSYSYT (SEQ ID NO: 24);

[0048] Preferably, the heavy chain variable region comprises the sequence of SEQ ID NO: 11, and the light chain variable region comprises the sequence of SEQ ID NO: 12

[0049] wherein the mutated Fc domain is a mutated Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutated Fc domain is a mutated Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutated Fc domain is a mutated Fc domain of an IgG1 antibody;

[0050] Most preferably, the antibody specifically binding to the CLDN18.2 molecule with the P329G mutation is HB37A6 PG Ab.

[0051] In some embodiments, in the pharmaceutical combination preparation described in the first aspect of the present invention, the content of the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule and comprises the P329G mutation in the preparation B is 8 to 12 mg / mL; preferably, the content of the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule and comprises the P329G mutation in the preparation B is 10.0 mg / mL;

[0052] The contents of the components of the pharmaceutical excipient II in the preparation B are: 5-20 mM pH regulator, 30-50 mg / mL osmotic pressure regulator, 0.005-0.02 mg / mL metal chelator, and 0.3-0.7 mg / mL surfactant;

[0053] Preferably, the contents of the components of the pharmaceutical excipient II in the preparation B are: 10 mM pH regulator, 39.53 mg / mL osmotic pressure regulator, 0.01 mg / mL metal chelator and 0.5 mg / mL surfactant;

[0054] More preferably, the contents of the components of the pharmaceutical excipient II in the preparation B are: 0.53 g / ml histidine, 1.38 mg / mL histidine hydrochloride, 29.00 mg / mL sorbitol, 10.53 mg / mL arginine hydrochloride, 0.01 mg / mL edetate disodium, and 0.5 mg / mL polysorbate 80;

[0055] Optionally, the pH of Formulation B is 5.8.

[0056] In some embodiments, the pharmaceutical combination preparation of the first aspect of the present invention, wherein the preparation A and preparation B are administered separately, simultaneously or sequentially.

[0057] In some embodiments, the pharmaceutical combination preparation according to the first aspect of the present invention, wherein the administration is parenteral administration; preferably, the administration is intravenous administration.

[0058] A second aspect of the present invention provides a use of the pharmaceutical combination formulation according to the first aspect of the present invention in the preparation of a medicament for treating and / or preventing cancer; preferably, the cancer is a cancer that expresses or overexpresses CLDN 18.2; more preferably, the cancer is a CLDN18.2-positive solid tumor.

[0059] The third aspect of the present invention provides a method for treating and / or preventing cancer, comprising administering the pharmaceutical combination formulation of the first aspect of the present invention to a subject in need thereof; preferably, the cancer is a cancer that expresses or overexpresses CLDN 18.2; more preferably, the cancer is a CLDN18.2-positive solid tumor.

[0060] In some embodiments, the method of the third aspect of the present invention is described, wherein the administration is parenteral administration; preferably, the administration is intravenous administration.

[0061] Effects of the Invention

[0062] It can be seen from the technical solution of the present invention that, compared with the prior art, the technical solution of the present invention has the following beneficial effects:

[0063] (1) In order to develop a stable CAR-T cell preparation, the types and addition ratios of various excipients of CAR-T cell preparations were studied, and a preparation formula that is conducive to the stability of CAR-T cells was screened. The final preparation formula for stable CAR-T cells was determined to be: 1E6 cells / mL to 1E8 cells / mL Hu968B chimeric antigen receptor (CAR)-T cells, 10.5% to 50.5% (v / v) of compound electrolyte injection, and 14.5% to 24.5% (v / v) of human serum albumin. CS10 50%~70% (v / v).

[0064] After being placed in liquid nitrogen vapor phase (≤-150℃) for 4 weeks, the cell viability of the preparation was >70%, no cell agglomeration occurred, and CD3 + CAR + There was no obvious change trend in the phenotype of T cells; after being placed at room temperature (22-26°C) for 4 hours, the cell viability of the preparation was >70% and no cell agglomeration occurred.

[0065] (2) In order to develop a stable formulation of recombinant anti-claudin 18.2 monoclonal antibody, the types and addition ratios of the excipients of the recombinant anti-claudin 18.2 monoclonal antibody formulation were studied, and a formulation formulation that was conducive to the stability of the recombinant anti-claudin 18.2 monoclonal antibody was screened out. The final formulation formulation for the stable recombinant anti-claudin 18.2 monoclonal antibody was determined to be: 10.0 mg / ml recombinant anti-claudin 18.2 monoclonal antibody, 0.53 mg / ml histidine, 1.38 mg / ml histidine hydrochloride, 29.00 mg / ml sorbitol, 10.53 mg / ml arginine hydrochloride, 0.01 mg / ml disodium edetate, 0.5 mg / ml polysorbate 80, pH 5.8.

[0066] After 4 weeks at 40°C ± 2°C, the purity of this formulation (non-reduced CE-SDS method) changed relatively slowly compared to other formulations. After 4 weeks at 40°C ± 2°C and 2 months at 25°C ± 2°C, the charge variants (iCIEF method) and the acidic components and main components of this formulation changed relatively slowly compared to other formulations. This formulation was also able to withstand 2 months at 5°C ± 3°C, 3 days of shaking (650 rpm, room temperature, protected from light), 6 freeze-thaw cycles, and 5 days of illumination (25°C ± 2°C, 500 Lux ± 50 Lux).

[0067] The above two drug preparations, when used in combination, have a killing effect on tumor cells and promote the release of cytokines. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 shows the structure of the CAR construct. In the figure, "SP" represents a signal peptide; "TMD" represents a transmembrane domain; "CSD" represents a costimulatory domain; and "SSD" represents a stimulatory signaling domain. In the construct, the extracellular domain comprises an antigen-binding portion that can specifically bind to a mutant Fc domain containing a P329G mutation, and the antigen-binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VH).

[0069] FIG2 shows a map of the pRK lentiviral expression vector.

[0070] FIG3 shows a diagram of the lentiviral expression vector after insertion of the CAR construct, digested with restriction endonucleases, and identified by electrophoresis.

[0071] Figure 4A shows the therapeutic effect of HuR968B CAR-T cells combined with different doses of P329G A6 antibody in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells.

[0072] FIG4B shows the changes in mouse body weight in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells and treated with HuR968B CAR-T cells combined with different doses of P329G A6 antibody.

[0073] Figure 4C shows the expansion of HuR968B CAR-T cells in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells induced by the combination of HuR968B CAR-T cells and different doses of P329G A6 antibodies.

[0074] FIG5A shows the therapeutic effect of HuR968B CAR-T cells combined with multiple doses of P329G antibody in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells.

[0075] Figure 5B shows the changes in mouse body weight caused by HuR968B CAR-T cells combined with multiple doses of P329G antibody in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells.

[0076] Figures 6A and 6B show the anti-tumor effects of different HuR968B CAR-T cell and P329G A6 antibody administration sequences in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells.

[0077] FIG7 shows the “predicted value - actual value” of the 0-hour survival rate after resuscitation.

[0078] FIG8 shows the “predicted value - actual value” of the survival rate 1 hour after resuscitation.

[0079] FIG9 shows the “predicted value - actual value” of the 2-hour survival rate after resuscitation.

[0080] FIG10 shows the “predicted value - actual value” of the 4-hour survival rate after resuscitation.

[0081] FIG11 shows the “predicted value - actual value” of the survival rate 8 hours after resuscitation.

[0082] FIG12 shows the importance of “alive rate 0h”, “alive rate 1h”, “alive rate 2h”, “alive rate 4h”, and “alive rate 8h” in the prediction profiler; the desirability function and the optimal condition.

[0083] FIG13 shows the change trend of the purity of the formulation screening (40° C., non-reduced CE-SDS method).

[0084] FIG14 shows the change trend of charge variants-acidic components (40° C., iCIEF method) in the formulation screening.

[0085] FIG15 shows the change trend of charge variant-principal component (40° C., iCIEF method) in prescription screening.

[0086] FIG16 shows the change trend of charge variants-acidic components (25° C., iCIEF method) in the formulation screening.

[0087] FIG17 shows the change trend of charge variants-principal components (25° C., iCIEF method) in prescription screening. DETAILED DESCRIPTION

[0088] Various exemplary embodiments, features, and aspects of the present invention will be described in detail below. The word "exemplary" is used herein to mean "serving as an example, embodiment, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as superior or preferred over other embodiments.

[0089] In addition, numerous specific details are provided in the following detailed description to better illustrate the present invention. Those skilled in the art will appreciate that the present invention can be practiced without certain specific details. In other instances, methods, means, equipment, and steps well known to those skilled in the art are not described in detail in order to highlight the main points of the present invention.

[0090] 1. Definition

[0091] To interpret this specification, the following definitions will apply, and wherever appropriate, terms used in the singular may also include the plural, and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0092] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.

[0093] As used herein, the term "and / or" means any one of the alternatives or two or more of the alternatives.

[0094] In this document, when the terms "comprising" or "including" are used, unless otherwise specified, it also covers the situation consisting of the recited elements, integers or steps. For example, when referring to an antibody variable region "comprising" a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.

[0095] The term "Claudins" refers to a class of integrin membrane proteins present in epithelial and endothelial tight junctions. They are important components of tight junctions and were discovered by Shoichiro Tsukita et al. in 1998. This family consists of 24 members. The human Claudin 18 gene has two alternative exons 1, resulting in two protein isoforms: Claudin 18.1 (also referred to herein as "CLDN18.1") and Claudin 18.2 (also referred to herein as "CLDN18.2"). These two protein isoforms differ by only seven amino acid residues in the approximately 50-amino acid sequence of the first extracellular domain.

[0096] There are significant differences in the expression of Claudin 18.2 between cancer tissues and normal tissues. This may be because the CREB binding site in the Claudin 18.2 promoter region is highly CpG methylated in normal tissues, while the CpG methylation level decreases during cell carcinogenesis, and CREB is involved in activating the transcription of Claudin18.2.

[0097] As used herein, the terms "CLDN18.2 antibody," "antibody against CLDN18.2," "antibody that specifically binds to CLDN18.2," "antibody that specifically targets CLDN18.2," and "antibody that specifically recognizes CLDN18.2" are used interchangeably to refer to antibodies that are capable of specifically binding to the claudin protein CLDN18.2. In particular, in some embodiments, they refer to antibodies that specifically bind to human CLDN18.2, particularly antibodies that specifically bind to human CLDN18.2 but not to human CLDN18.1.

[0098] The term "antibody" is used in the broadest sense herein to refer to a protein comprising an antigen binding site, encompassing natural and artificial antibodies of various structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, complete antibodies, and antibody fragments. Preferably, the antibody of the present invention is a single domain antibody or a heavy chain antibody.

[0099] "Antibody fragment" or "antigen-binding fragment" are used interchangeably herein to refer to a molecule other than an intact antibody that comprises a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, single-chain Fv, single-chain Fab, and diabody.

[0100] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are optionally continuously connected by a flexible short polypeptide linker and can be expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise indicated, as used herein, scFv can have the VL variable region and the VH variable region in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and the scFv can comprise VL-linker-VH or can comprise VH-linker-VL.

[0101] "Complementarity determining region" or "CDR region" or "CDR" or "hypervariable region" is a region in an antibody variable domain that is highly variable in sequence and forms structurally determined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of the heavy and light chains are typically referred to as CDR1, CDR2, and CDR3, and are numbered sequentially starting from the N-terminus. The CDRs located within the antibody heavy chain variable domain are referred to as CDR H1, CDR H2, and CDR H3, while the CDRs located within the antibody light chain variable domain are referred to as CDR L1, CDR L2, and CDR L3. In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics database (IMGT) (world wide web imgt.cines.fr / ), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures.

[0102] Unless otherwise indicated, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined in any of the above-mentioned ways.

[0103] CDR can also be determined based on having the same Kabat numbering position as a reference CDR sequence (e.g., any of the CDRs exemplified herein). In the present invention, when referring to antibody variable regions and specific CDR sequences (including heavy chain variable region residues), it refers to the numbering position according to the Kabat numbering system.

[0104] Although CDR is different between antibodies, only a limited number of amino acid positions in CDR are directly involved in antigen binding. Using at least two of the Kabat, Chothia, AbM and Contact methods, the minimum overlapping region can be determined, thereby providing a "minimum binding unit" for antigen binding. The minimum binding unit can be a sub-portion of a CDR. As those skilled in the art will appreciate, the residues of the remainder of the CDR sequence can be determined by the structure and protein folding of the antibody. Therefore, the present invention also contemplates variants of any CDR provided herein. For example, in a variant of a CDR, the amino acid residues of the minimum binding unit can remain unchanged, while the remaining CDR residues defined according to Kabat or Chothia or AbM can be replaced by conservative amino acid residues.

[0105] The term "chimeric antibody" is an antibody molecule in which (a) the constant region or a portion thereof is changed, replaced or exchanged so that the antigen binding site is connected to a constant region of a different or altered class and / or species or a completely different molecule (e.g., enzyme, toxin, hormone, growth factor, drug) that confers new properties to the chimeric antibody; or (b) the variable region or a portion thereof is changed, replaced or exchanged with a variable region having a different or altered antigenic specificity. For example, a mouse antibody can be modified by replacing its constant region with a constant region from a human immunoglobulin. Due to the replacement with a human constant region, the chimeric antibody can retain its specificity in recognizing the antigen while having reduced antigenicity in humans as compared to the original mouse antibody.

[0106] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, which comprises at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In certain embodiments, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carbonyl end of the heavy chain. However, the C-terminal lysine (Lys447) in the Fc region may or may not be present. Unless otherwise indicated, the numbering of the amino acid residues in the Fc region or constant region is according to the EU numbering system, which is also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0107] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to the antigen. The variable domains of the heavy and light chains of natural antibodies generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementarity determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co. 91 p. (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

[0108] As used herein, the term "binding" or "specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antibody to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA), SPR or biofilm interferometry or other conventional binding assays known in the art.

[0109] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex) to its corresponding ligand, which thereby mediates a signal transduction event, such as, but not limited to, signal transduction via the TCR / CD3 complex. Stimulation can mediate the expression of certain molecules, such as downregulation of TGF-β and / or reorganization of cytoskeletal structure.

[0110] The term "stimulatory molecule" refers to a molecule expressed by a T cell that provides a primary cytoplasmic signaling sequence that regulates the primary activation of the TCR complex in a stimulatory manner in at least some aspect of the T cell signaling pathway. In one embodiment, the primary signal is initiated, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule and results in mediating a T cell response, including but not limited to proliferation, activation, differentiation, and the like. In the specific CARs of the present invention, the intracellular signaling domain in any one or more CARs of the present invention comprises an intracellular signaling sequence, for example, the primary signaling sequence of CD3ζ.

[0111] The term "CD3 ζ" is defined as a protein or its equivalent provided by GenBank accession number BAG36664.1, and "CD3 ζ stimulatory signaling domain" is defined as the amino acid residues from the cytoplasmic domain of the CD3 ζ chain that are sufficient to functionally propagate the initial signal necessary for T cell activation. In one embodiment, the cytoplasmic domain of CD3 ζ comprises residues 52 to residue 164 of GenBank accession number BAG36664.1 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.) as their functional homologs. In one embodiment, the "CD3 ζ stimulatory signaling domain" is the sequence provided in SEQ ID NO:8 or a variant thereof.

[0112] The term " costimulatory molecules " refers to the corresponding binding partners on the cell that specifically bind to the costimulatory reaction (such as but not limited to proliferation) of the costimulatory ligands so as to mediate the costimulatory response of the cell.Costimulatory molecules are cell surface molecules that contribute to effective immune response except antigen receptors or their ligands.Costimulatory molecules include but are not limited to MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal transduction lymphocyte activation molecules (SLAM proteins), activation NK cell receptors, OX40, CD40, GITR, 4-1BB (i.e. CD137), CD27 and CD28. In some embodiments, " costimulatory molecules " are CD28, 4-1BB (i.e. CD137). The costimulatory signal domain refers to the intracellular part of the costimulatory molecules.

[0113] The term "4-1BB" refers to a member of the TNFR superfamily having an amino acid sequence as provided in GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.); and "4-1BB costimulatory signaling domain" is defined as amino acid residues 214-255 of GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.). In one embodiment, the "4-1BB costimulatory domain" is a sequence provided as SEQ ID NO: 7 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.).

[0114] The term "signaling pathway" refers to the biochemical relationships between various signaling molecules that play a role in propagating a signal from one part of a cell to another part of the cell.

[0115] The term "cytokine" is a generic term for proteins released by one cell population that act as intercellular mediators on another cell. Examples of such cytokines include lymphokines, monokines, interleukins (ILs), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, and IL-15; tumor necrosis factors, such as TNF-α and TNF-β; and other polypeptide factors, including interferon-γ.

[0116] An "isolated" antibody is one that has been separated from the components of its natural environment. In some embodiments, the antibodies of the invention are purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0117] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. An "isolated nucleic acid encoding an antibody of the invention" refers to one or more nucleic acid molecules that encode a chain of an antibody of the invention or a fragment thereof, including such nucleic acid molecules in a single vector or separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.

[0118] The term "autologous" refers to any substance that is derived from the same individual into whom the substance is later reintroduced.

[0119] The term "allogeneic" refers to any substance derived from an animal of the same species as the individual into which the substance is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic substances from individuals of the same species can be sufficiently genetically dissimilar to interact antigenically.

[0120] The term "xenogeneic" refers to a graft derived from an animal of a different species.

[0121] As used herein, the term "apheresis" refers to an art-recognized in vitro method whereby blood from a donor or patient is removed from the donor or patient and passed through a device that separates selected specific components and returns the remainder to the donor's or patient's circulation, for example, by retransfusion. Thus, in the context of an "apheresis sample," a sample obtained using apheresis is referred to.

[0122] The term "immune effector cell" refers to a cell that participates in an immune response, e.g., participates in promoting an immune effector reaction. Examples of immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.

[0123] "Immune effector function," "immune effector response," or "immune effector reaction" refers to, for example, a function or response of an immune effector cell that enhances or promotes immune attack on a target cell. For example, an immune effector function or response refers to a property of a T cell or NK cell that promotes killing of a target cell or inhibits growth or proliferation of a target cell. In the case of T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.

[0124] The term "effector function" refers to a specialized function of a cell. The effector function of a T cell may be, for example, cytolytic activity or helper activity, including the secretion of cytokines.

[0125] The term "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from the group consisting of proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. The chimeric antigen receptors of the present invention are capable of inducing T cell activation. Suitable assays for measuring T cell activation are described in the Examples and are known in the art.

[0126] The term "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in their ability to infect non-dividing cells; they can deliver significant amounts of genetic information to host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.

[0127] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, and particularly includes self-inactivating lentiviral vectors such as those provided in Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). Other examples of lentiviral vectors that can be used clinically include, but are not limited to, those from Oxford BioMedica. Gene delivery technology, LENTIMAX from Lentigen TM Vector systems, etc. Non-clinical types of lentiviral vectors are also available and known to those skilled in the art.

[0128] The term "disease associated with CLDN18.2" refers to any condition caused by, exacerbated by, or otherwise associated with increased expression or activity of CLDN18.2 (such as human CLDN18.2).

[0129] The terms "individual" or "subject" are used interchangeably and include mammals. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.

[0130] The terms "tumor" and "cancer" are used interchangeably herein to encompass both solid and liquid tumors.

[0131] The terms "cancer" and "cancerous" refer to the physiological condition in mammals characterized by unregulated cell growth.

[0132] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer," "cancerous," and "tumor" are not mutually exclusive when referred to herein.

[0133] "Tumor immune escape" refers to the process by which a tumor evades immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when this evasion is compromised, allowing the tumor to be recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage, and tumor clearance.

[0134] The term "median effective concentration (EC50)50 )" refers to the concentration of drug, antibody or toxic agent that induces a response that is 50% between baseline and maximum after a specified exposure time.

[0135] The term "fluorescence activated cell sorting" or "FACS" refers to a specialized type of flow cytometry. It provides a method for sorting a heterogeneous mixture of biological cells into two or more containers one cell at a time based on the specific light scattering and fluorescence characteristics of each cell (FlowMetric. "Sorting Out Fluorescence Activated Cell Sorting". 2017-11-09). Instruments for performing FACS are known to those skilled in the art and are commercially available to the public. Examples of such instruments include the FACS Star Plus, FACScan, and FACSort instruments from Becton Dickinson (Foster City, CA), the Epics C from Coulter Epics Division (Hialeah, FL), and the MoFlo from Cytomation (Colorado Springs, Colorado).

[0136] The term "pharmaceutically acceptable excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, buffer, stabilizer, or the like, which is administered together with the active substance.

[0137] As used herein, "treat" refers to slowing, interrupting, retarding, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibody molecules of the present invention are used to delay disease progression or to slow the progression of a disease.

[0138] The term "effective amount" refers to an amount or dosage of an antibody or composition of the present invention that produces the desired effect in a patient in need of treatment or prevention after administration to the patient in a single or multiple doses. The effective amount can be readily determined by the attending physician, who is skilled in the art, by considering a variety of factors such as the species of the mammal; weight, age, and general health; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosing regimen; and the use of any concomitant therapy.

[0139] A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. A therapeutically effective amount of an antibody or antibody fragment or composition thereof can vary depending on a variety of factors, such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or composition thereof are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70%, and still more preferably at least about 80% or 90% relative to an untreated subject. The ability of a compound to inhibit a measurable parameter (e.g., cancer) can be evaluated in an animal model system that is predictive of efficacy in human tumors.

[0140] The term "drug combination" refers to a non-fixed combination product or a fixed combination product, including but not limited to a kit and a pharmaceutical composition. The term "non-fixed combination" means that the active ingredients (e.g., (i) P329G CAR-T cells and (ii) antibodies against the CLDN18.2 P329G mutant) are administered to a subject simultaneously, without specific time limits, or at the same or different time intervals, sequentially as separate entities, wherein such administration provides effective treatment in the subject. The term "fixed combination" refers to a combination of antibodies against the CLDN18.2 P329G mutant and P329G CAR-T cells of the present invention, each administered to a patient simultaneously in the form of a specific single dose. The term "non-fixed combination" means that a combination of antibodies against the CLDN18.2 P329G mutant and P329G CAR-T cells of the present invention are administered to a patient simultaneously, in parallel, or sequentially as separate entities, without specific dosage and time limits, wherein such administration provides a therapeutically effective level of the drug combination of the present invention in the patient. In a preferred embodiment, the drug combination is a non-fixed combination.

[0141] The term "vector," as used herein when referring to nucleic acids, refers to a nucleic acid molecule that is capable of propagating another nucleic acid to which it is attached. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operatively attached. Such vectors are referred to herein as "expression vectors."

[0142] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived therefrom, without considering the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. Included herein are mutant progeny with the same function or biological activity that have been screened or selected in the initially transformed cells. Host cells are any type of cell system that can be used to produce the antibody molecules of the present invention, including eukaryotic cells, for example, mammalian cells, insect cells, yeast cells; and prokaryotic cells, for example, Escherichia coli cells. Host cells include cultured cells, as well as cells within transgenic animals, transgenic plants, or cultured plant tissues or animal tissues.

[0143] "Subject / patient sample" refers to a collection of cells, tissues, or body fluids obtained from a patient or subject. The source of the tissue or cell sample can be a solid tissue, such as an organ or tissue sample or a biopsy sample or a puncture sample from a fresh, frozen, and / or preserved organ or tissue sample; blood or any blood component; body fluids, such as cerebrospinal fluid, amniotic fluid (amniotic fluid), peritoneal fluid (ascites), or interstitial fluid; cells from any time during the subject's pregnancy or development. Tissue samples may contain compounds that are not naturally mixed with tissues in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like. Examples of tumor samples herein include, but are not limited to, tumor biopsies, fine needle aspirates, bronchial lavage fluid, pleural fluid (pleural effusion), sputum, urine, surgical specimens, circulating tumor cells, serum, plasma, circulating plasma proteins, ascites, primary cell cultures or cell lines derived from tumors or exhibiting tumor-like properties, and preserved tumor samples, such as formalin-fixed, paraffin-embedded tumor samples or frozen tumor samples.

[0144] The term "treat" with reference to a disease means to alleviate the disease (ie, slow or arrest or reduce the development of the disease or at least one clinical symptom thereof), prevent or delay the onset or development or progression of the disease.

[0145] The term "cell viability" refers to the percentage of living cells in a total cell population.

[0146] The term "cell clumping rate" refers to the degree of cell aggregation and is an important indicator for evaluating the safety of cell therapy products.

[0147] The term "MOI" refers to the ratio of the number of viruses (bacteriophages) to the number of bacteria when the virus (bacteriophage) infects the bacteria, that is, the average number of viruses (bacteriophages) that infect each bacterium.

[0148] The term "CE-SDS" refers to the capillary electrophoresis with sodium dodecyl sulfate (CE-SDS) with ultraviolet detection method, which quantitatively determines the purity of recombinant monoclonal antibody products based on molecular weight by capillary electrophoresis under reducing and non-reducing conditions.

[0149] The term "SEC-HPLC" refers to size exclusion chromatography-high performance liquid chromatography detection method.

[0150] The term "main component" refers to the target product. The higher the purity, the more target product is obtained.

[0151] The term "charge variant" is due to the fact that protein products undergo post-translational modification and degradation events in cells, resulting in heterogeneity in biophysical properties and differences in the charges they carry, hence the name charge variant.

[0152] The term "acidic charge variant" refers to charge variants that appear earlier or later than the main peak in different analytical methods. Acidic charge variants can arise for a variety of reasons, including potential modifications that affect product bioactivity. Therefore, the presence of acidic charge variants is often used as an indicator of antibody product quality.

[0153] 2. Molecular switch-regulated chimeric antigen receptor (CAR) of the present invention, nucleic acid molecules encoding the CAR of the present invention, vectors, and cells expressing the CAR of the present invention

[0154] The present invention relates to chimeric antigen receptor polypeptides capable of specifically binding to a mutant Fc domain of an antibody against CLDN18.2. Specifically, the chimeric antigen receptor of the present invention comprises a humanized anti-P329G mutant scFv sequence, and the scFv sequence is capable of specifically binding to an antibody Fc domain comprising the P329G mutation, but is unable to specifically bind to the unmutated parent antibody Fc domain. Compared to the binding of the unmutated parent antibody Fc domain to the Fc receptor, the antibody Fc domain comprising the P329G mutation has reduced binding to Fc receptors (e.g., Fcγ receptors).

[0155] The recombinant CAR construct of the present invention comprises a sequence encoding CAR, wherein the CAR comprises a humanized anti-P329G mutation scFv sequence, and the scFv sequence specifically binds to the antibody Fc domain of the P329G mutation.

[0156] In one embodiment, the scFv sequence in the CAR construct of the present invention comprises the following sequence:

[0157] (i) a heavy chain variable region comprising a

[0158] (a) heavy chain complementarity determining region CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 13);

[0159] (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 14); and

[0160] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 15); and

[0161] (ii) a light chain variable region comprising a

[0162] (d) light chain complementarity determining region CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 16);

[0163] (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 17); and

[0164] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 18),

[0165] Wherein the scFv can be linked to a signal peptide sequence at the N-terminus, for example, the signal peptide sequence shown in SEQ ID NO: 1, and the scFv can be linked to a hinge region / spacer sequence as provided in SEQ ID NO: 5, a transmembrane region as provided in SEQ ID NO: 6, a costimulatory signaling domain as provided in SEQ ID NO: 7, and an intracellular stimulatory signaling domain comprising SEQ ID NO: 8 at the C-terminus, for example, wherein the respective domains are adjacent to each other and are in the same reading frame to form a single fusion protein.

[0166] In some embodiments, the scFv domain comprises (i) a heavy chain variable region comprising the sequence of SEQ ID NO: 2, and (ii) a light chain variable region comprising the sequence of SEQ ID NO: 3;

[0167] In some embodiments, the scFv domain comprises (i) a heavy chain variable region set forth in SEQ ID NO: 2 and (ii) a light chain variable region set forth in SEQ ID NO: 3. In one embodiment, the scFv domain further comprises a (Gly4-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4. The light chain variable region and the heavy chain variable region of the scFv can be, for example, in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

[0168] In some embodiments, the present invention provides the amino acid sequence of the full-length CAR polypeptide as SEQ ID NO: 9, as shown in the sequence listing.

[0169] In some embodiments, the present invention provides a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR of the present invention. For example, the nucleic acid sequence of the CAR construct of the present invention is SEQ ID NO: 10. Recombinant methods known in the art can be used to obtain a CAR construct encoding the present invention. Alternatively, the target nucleic acid can be produced synthetically rather than by genetic recombination methods.

[0170] The present invention includes retroviral and lentiviral vector constructs that express CARs that can be directly transduced into cells.

[0171] In some embodiments, the nucleic acid sequence of the CAR construct of the present invention is cloned into a lentiviral vector to generate a full-length CAR construct in a single coding frame, and the EF1α promoter is used for expression.

[0172] The present invention provides nucleic acid molecules encoding CAR constructs described herein.In one embodiment, the nucleic acid molecule is provided as a DNA construct.

[0173] In some embodiments, the CAR construct comprises the nucleotide sequence shown in SEQ ID NO:10.

[0174] The present invention also provides a vector having a CAR construct of the present invention inserted therein. By effectively connecting the nucleic acid encoding the CAR polypeptide to a promoter and incorporating the construct into an expression vector, the expression of the natural or synthetic nucleic acid encoding the CAR is achieved. The vector may be suitable for replication and integration in eukaryotic organisms. Common cloning vectors contain transcription and translation terminators, initiation sequences, and promoters for regulating the expression of the desired nucleic acid sequence.

[0175] In some embodiments, the present invention provides methods of expressing a CAR construct of the invention in a mammalian immune effector cell (e.g., a mammalian T cell) and the immune effector cells (e.g., T cells) produced thereby.

[0176] 3. Antibodies that specifically bind to CLDN18.2 molecules and antibodies containing mutant Fc domains

[0177] The present inventors have developed a class of anti-CLDN18.2 antibodies that specifically recognize CLDN18.2 with suitable affinity, comprising a heavy chain variable region and a light chain variable region, wherein:

[0178] The heavy chain variable region comprises CDR H1 shown by the amino acid sequence SYVMS (SEQ ID NO: 19) according to the Kabat numbering; CDR H2 shown by the amino acid sequence TISHSGGSTYYADSVKG (SEQ ID NO: 20); and CDR H3 shown by the amino acid sequence DAPYYDILTGYRY (SEQ ID NO: 21); the light chain variable region comprises CDR L1 shown by the amino acid sequence RASQSISSWLA (SEQ ID NO: 22) according to the Kabat numbering; CDR L2 shown by the amino acid sequence KASSLES (SEQ ID NO: 23); and CDR L3 shown by the amino acid sequence QQYNSYSYT (SEQ ID NO: 24).

[0179] In some embodiments, the antibodies of the present invention that bind to CLDN18.2 molecules comprise a heavy chain variable region and a light chain variable region that specifically bind to CLDN18.2 but do not bind or do not substantially bind to CLDN18.1, wherein:

[0180] The heavy chain variable region comprises the sequence of SEQ ID NO: 11, and the light chain variable region comprises the sequence of SEQ ID NO: 12.

[0181] In some embodiments, the antibody of the present invention that binds to a CLDN18.2 molecule is an IgG1, IgG2, IgG3, or IgG4 antibody; preferably, it is an IgG1 or IgG4 antibody; more preferably, it is an IgG1 antibody, for example, a human IgG1 antibody.

[0182] In some embodiments, the antibodies provided herein that bind to the CLDN18.2 molecule comprise a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G), and the Fcγ receptor binding of the mutant Fc domain is reduced compared to the Fcγ receptor binding of the unmutated parent antibody Fc domain; for example, the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody, for example, the mutant Fc domain is a mutant Fc domain of a human IgG1 antibody.

[0183] Antibodies that bind to CLDN18.2 molecules and contain a P329G mutant Fc domain cannot exert antibody-dependent cellular cytotoxicity by binding to Fcγ receptors, nor can they exert complement-dependent cytotoxicity, and therefore cannot kill CLDN18.2-positive cancer cells.

[0184] 4. The drug combination of the present invention

[0185] For optimizing the safety and efficacy of CAR therapy, the molecular switch regulated chimeric antigen receptor of the present invention is a regulatable CAR that can control the activity of CAR. The present invention uses Pro329Gly (antibody Fc segment mutates proline 329 to glycine according to EU numbering, abbreviated as P329G or PG) mutant antibody as a safety switch in the CAR treatment of the present invention. In the absence of the P329G mutant antibody, the CAR activity of the present invention is turned off; in the presence of the P329G mutant antibody, the CAR activity of the present invention is turned on; thus, the opening and closing of the CAR molecule activity of the present invention is regulated by the P329G mutant antibody.

[0186] In some embodiments, the present invention provides a drug combination, which includes (i) immune effector cells (e.g., T cells) expressing the molecular switch regulating CAR polypeptides of the present invention; and (ii) P329G mutant antibodies specifically binding to CLDN18.2 molecules. For example, the immune effector cells are T cells expressing the molecular switch regulating CAR polypeptides of the present invention prepared from autologous T cells or allogeneic T cells, for example, the immune effector cells are T cells expressing the molecular switch regulating CAR polypeptides of the present invention prepared from T cells separated from human PBMC. In some embodiments, the P329G mutant antibody is HB37A6 PG Ab.

[0187] In some embodiments, the present invention provides a drug combination comprising (i) a nucleic acid molecule encoding a molecular switch-regulated CAR polypeptide of the present invention or a vector comprising the nucleic acid component; and (ii) a P329G mutant antibody that specifically binds to the CLDN18.2 molecule.

[0188] In some embodiments, the pharmaceutical combination of the present invention optionally further comprises the pharmaceutically acceptable excipients of suitable formulations. For example, (ii) in the pharmaceutical combination can be formulated according to conventional methods (e.g., Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, USA). Pharmaceutically acceptable excipients can be exemplified by surfactants, excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents, isotonic agents, adhesives, disintegrants, lubricants, flow promoters, flavoring agents, etc. Further, other commonly used carriers can also be suitably used, for example, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carboxymethylcellulose calcium, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylamino acetate, polyvinyl pyrrolidone, gelatin, medium chain fatty acid triglycerides, polyoxyethylene hardened castor oil 60, white granulated sugar, carboxymethyl cellulose, corn starch, inorganic salts, etc. as carriers, but are not limited thereto.

[0189] In some embodiments, the pharmaceutical combination of the present invention is used to treat a disease associated with CLDN18.2, such as a cancer that expresses or overexpresses CLDN18.2, such as a CLDN18.2-positive solid tumor.

[0190] Example

[0191] The embodiments of the present invention will be described in detail below with reference to the examples, but it will be understood by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0192] Example 1. CAR gene synthesis and viral expression vector construction

[0193] The DNA fragment shown in SEQ ID NO: 10 was artificially synthesized, and the DNA fragment encoded the amino acid sequence shown in SEQ ID NO: 9, which corresponds to the HuR968B CAR construct shown in FIG1 .

[0194] The CAR construct (hereinafter sometimes referred to as P329CAR; P329G CAR; PG CAR) comprises an amino-terminal (N-terminal) signal peptide sequence (SEQ ID NO: 1), an anti-P329G mutant antibody heavy chain variable region VH sequence (SEQ ID NO: 2), a linker sequence (SEQ ID NO: 4), an anti-P329G mutant antibody light chain variable region VL (SEQ ID NO: 3), a G4S hinge region sequence (SEQ ID NO: 5), a transmembrane region sequence derived from a CD8 molecule (SEQ ID NO: 6), a costimulatory signal sequence derived from a 4-1BB molecule (SEQ ID NO: 7), and an intracellular stimulatory signal domain derived from a CD3 ζ chain (CD247) (SEQ ID NO: 8).

[0195] The various elements of the pRK lentiviral expression vector are shown in Figure 2. The above-mentioned DNA fragments encoding the CAR polypeptide were inserted into the downstream of the EF1α promoter of the pRK lentiviral expression vector (modified by replacing the promoter and resistance gene of the pRRLSIN.cPPT.PGK-GFP.WPRE vector (Addgene, 12252, purchased from Biowind)), replacing the EGFR sequence in the vector, and obtaining CAR expression plasmids (pRK-HuR968B) targeting the P329G mutation or various controls.

[0196] The lentiviral expression vector for expressing CAR was digested with restriction endonucleases and identified by electrophoresis. The results are shown in FIG3 , indicating that the lentiviral expression vector for expressing CAR was correctly constructed.

[0197] Example 2. Preparation of CAR-T cells

[0198] (2-1) Preparation of lentiviral concentrate

[0199] The CAR expression plasmid prepared in Example 1 was transfected into Lenti-X-293T cells (Takara) at a mass ratio of 3:3:2:2 using the PEI transfection method with the structural plasmid pMDLg / pRRE (Addgene, 12251, purchased from Biowind), the regulatory plasmid pRSV-rev (Addgene, 12253, purchased from Biowind) and the envelope plasmid pMD2G (Addgene, 12259, purchased from Biowind) at a mass ratio of 3:3:2:2. After 16 hours of transfection, the medium was replaced with fresh DEME medium containing 2% fetal bovine serum (FBS). After 48 hours of culture, the cell supernatant was collected and centrifuged to remove cell debris. PEG8000 was added and incubated at 4°C for 16-64 hours for lentivirus concentration. After centrifugation again, the supernatant was removed and the lentivirus precipitate was resuspended in T cell culture medium to obtain a lentivirus concentrate, which was then packaged and frozen at -80°C.

[0200] (2-2) Lentiviral titer detection

[0201] Lenti-X-293T cells (Takara) were digested and resuspended in DMEM medium containing 8 μg / ml Polybrene (Sigma, H9268-5G). The cell suspension was added to a 24-well plate, and different volumes of the lentiviral concentrate obtained in Example 2-1 were added and cultured for 72 hours for transduction of 293T cells.

[0202] 293T cells transduced with the lentiviral concentrate were digested and stained with biotin-SP-conjugated anti-human IgG, F(ab')2-specific (Jackson ImmunoResearch, 109-066-006) and APC-Streptadvidin (BioLegend, 405207). The proportion of APC-positive cells was determined by flow cytometry. Viral titer (TU / ml) was calculated based on the starting cell amount, viral volume, and the proportion of positive cells.

[0203] (2-3) T cell sorting, infection, and CAR-T cell expansion and culture

[0204] Recombinant human interleukin-2 for injection (National Medical Products Administration No. S20040020) was added to TexMACS GMP Medium (Miltenyi Biotec, 170-076-309) to prepare a T cell culture medium with an IL-2 concentration of 200 IU / ml.

[0205] On day 0, the revived PBMCs were sorted using the Pan T Cell Isolation Kit (human) (Miltenyi, 130-096-535) to obtain T cells, which were resuspended to a certain density in T cell culture medium and activated with TransAct (Miltenyi, 130-111-160).

[0206] On the first day, a certain amount of T cells were separated and cultured without adding lentivirus. These cells were untransduced cells (UNT, un-transduced T cells). Different types of lentivirus concentrates obtained from Example 2-1 were added to the remaining cells at an MOI of 1 to 5, and the T cells were blown evenly. On the second day, the viral supernatant was removed by centrifugation, and the cells were resuspended in fresh T cell culture medium. UNT cells were not operated on. On the third day, all cells were transferred to G-Rex (WILSONWOLF, item number 80040S), and an appropriate amount of fresh T cell culture medium was added, and the cells were placed in a 37°C CO2 incubator for static culture. Every 2 to 3 days, the cells were replaced with half the amount of culture medium with fresh culture medium or IL-2 was directly added, wherein the IL-2 concentration in the cell culture medium was 200 IU / ml. When the cell number was expanded to about 20-80 times, after meeting the requirements (generally reaching 2 to 8×10 8 Cells were harvested to obtain HuR968B CAR-T cells. After centrifugation to remove the culture medium, CAR-T cells were used CS10 (Stemcell, 07930) was resuspended and aliquoted, then programmed to cool to -80°C for freezing.

[0207] Example 3 Synthesis of CLDN18.2-specific WT antibody and P329G mutant antibody

[0208] The light and heavy chain variable regions of the CLDN18.2 antibody HB37A6 (also referred to as A6 antibody in this article) were cloned (SEQ ID NO: 11, SEQ ID NO: 12) from the patent (patent application number: PCT / CN2021 / 100870); the light and heavy chain variable region sequences of the 175D10 clone (SEQ ID NO: 25, SEQ ID NO: 26) were obtained from the US10813996B2 patent as a positive control antibody (Zolbetuximab, Zmab); the antibody light and heavy chain variable region nucleotide sequences were synthesized using whole-gene synthesis and loaded into a pcDNA3.4 expression vector (purchased from Shanghai Boying) containing the WT human IgG1 heavy chain constant region (SEQ ID NO: 27) or the P329G point mutated human IgG1 heavy chain constant region (SEQ ID NO: 28) and κ light chain constant region (SEQ ID NO: 29) sequences. The light and heavy chain expression vectors were co-transfected into HEK293 cells using polyethylene glycol (PEI) at a molar ratio of 2:3. After 5-7 days of culture, the culture supernatant was collected. The antibody-containing supernatant was purified using a Protein A column and then dialyzed against PBS. This yielded CLDN18.2-specific WT antibody and P329G mutant antibody. The CLDN18.2-specific WT antibody is also referred to as "HB37A6" ​​or "A6" antibody, while the antibody containing the P329G mutation is also referred to as "HB37A6 PG Ab," "A6 PG" antibody, or "A6-PG antibody." Concentration was determined by absorbance at 280 nm using a NanoDrop instrument, and sample purity was assessed by SDS-PAGE and SEC-HPLC.

[0209] Example 4: Study on the anti-tumor effect of HuR968B CAR-T cells combined with HB37A6 PG antibody after single administration in vivo

[0210] (4-1) Tumor inoculation and treatment in mice, and anti-tumor effects

[0211] DAN-G18.2 cells (constructed by Innoventbio’s new drug department, the specific construction method is the same as the construction of the DAN-G-CLDN18.2 tumor cell line described in patent application PCT / CN2021 / 100870) were resuspended in 1× PBS and prepared to a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and injected subcutaneously with 5×10 6 DAN-G18.2 cell suspension (0.2 mL / cell), i.e., the inoculation volume is 1×10 6 7 days after tumor cell inoculation, the tumor volume of mice ranged from 72.13 to 113.94 mm3 The mice were divided into 5 groups, including vehicle group, 8B CAR-T group (HuR968B CAR-T is abbreviated as "8BCAR-T"), 8B CAR-T+A6-PG (0.03 mg / kg) group, 8B CAR-T+A6-PG (0.1 mg / kg) group and 8B CAR-T+A6-PG (0.3 mg / kg) group, with 7-14 mice in each group. 8B CAR-T cells were resuspended in 1× PBS to prepare 8B CAR + The cells were 2.5×10 7 CAR was injected into the tail vein at a rate of 0.2 mL per mouse. + Cells 5×10 6 The antibody was administered intraperitoneally as a single dose on day 1 after CAR-T cell infusion, which was 8 days after tumor cell inoculation. Mouse body weight and the maximum longitudinal axis (L) and maximum width (W) of tumor tissue were monitored twice weekly.

[0212] Figure 4A shows the therapeutic effects of HuR968B CAR-T cells combined with different doses of the P329G A6 antibody in immunodeficient mice inoculated with human DAN-G18.2 tumor cells. The results showed that HuR968B CAR-T cells induced a significant anti-tumor effect when coadministered with a P329G A6 antibody dose as low as 0.03 mg / kg. Increasing the P329G A6 antibody dose to 0.1 and 0.3 mg / kg did not significantly increase the maximum anti-tumor effect induced by HuR968B CAR-T cells, but the anti-tumor effect was more sustained. Two weeks after treatment, the tumor growth inhibition (TGI) in the 0.03, 0.1, and 0.3 mg / kg treatment groups was 84.6%, 88.7%, and 91.3%, respectively. Three weeks after treatment, the TGI was 75.9%, 77.6%, and 90.0%, respectively. The CAR-T cell alone group showed no anti-tumor effect.

[0213] Figure 4B shows the changes in mouse weight during this experiment. The results showed that the weight of mice treated with HuR968B CAR-T cells and P329G A6 antibody began to decrease after treatment, reaching its lowest point 9 days after co-administration of P329G A6 antibody. The average weight reductions in the 0.03, 0.1, and 0.3 mg / kg treatment groups were 13.5%, 20.6%, and 24.4%, respectively. Subsequently, the mice began to recover, with the 0.03 and 0.1 mg / kg treatment groups returning to normal weight within 4 days, and the 0.3 mg / kg treatment group also returning to normal weight after 1 week. These results indicate that HuR968B CAR-T cells combined with low-dose P329G A6 antibody treatment induced a significant anti-tumor effect, but also produced transient, tolerable side effects.

[0214] (4-2) In vivo CAR-T cell detection:

[0215] The method is as follows:

[0216] Take 30 μL of mouse blood sample and add it to a 96-well V-well plate, marked as the sample test well; take 10 μL of mouse blood sample and add it to a 96-well V-well plate, marked as the control well. Add 100 μL of LIVE / DEAD Fixable Dead Cell Stain and TruStain FcX to all wells. TM (anti-mouse CD16 / 32) (Biolegend) FACS buffer, gently mix, and incubate at 4°C in the dark for 15 minutes; then add Biotin-F(ab′)2 fragment goat anti-human IgG antibody to the sample detection wells and incubate at 4°C in the dark for 30 minutes; then add 100 μL FACS buffer to each sample detection well, centrifuge at 400g, and discard the supernatant; add 100 μL FACS buffer containing APC-Cy7 anti-human CD45 (Biolegend), PerCP-Cy5.5-CD3 (BD ​​Biosciences) and APC-streptavidin (Biolegend) to each well, gently mix, and incubate at 4°C in the dark for 30 minutes; then add 200 μL / well FACS buffer to all wells, centrifuge at 400g, and discard the supernatant; then add 250 μL / well 1× RBC Lysis / Fixation solution (Biolegend), mix well, incubate at room temperature in the dark for 20 min; centrifuge at 400 g, discard the supernatant; resuspend the cells in 100 μL FACS buffer, add 10 μL 123count eBeads to each well, and detect using flow cytometer.

[0217] Figure 4C shows the expansion of HuR968B CAR-T cells in mice in the experiment of Example 4-1. The results showed that HuR968B CAR-T cells began to expand one week after being infused back into the mice, reached a peak level after two weeks, and then rapidly declined, returning to baseline levels after three weeks. The expansion of CAR-T cells in vivo depends on the P329G A6 antibody. Mice in the group not given the antibody at the same time did not show obvious cell expansion; in addition, CAR-T cell expansion showed a certain dose dependence of P329G A6 antibody. Mice in the higher dose group had higher levels of CAR-T cell expansion. The peak expansion levels of the 0.03, 0.1, and 0.3 mg / kg dose groups were 121783, 135765, and 180927 cells / 100μl peripheral blood, respectively, which were much higher than the group not given the antibody at the same time (12160 cells / 100μl peripheral blood).

[0218] Example 5: Study on the anti-tumor effect of multiple administrations of HuR968B CAR-T cells combined with HB37A6 PG antibody in vivo

[0219] Mouse tumor inoculation and treatment were performed. DAN-G18.2 cells were resuspended in 1× PBS to a cell concentration of 5×10 6 NOG mice were shaved on the right side of their backs and injected subcutaneously with 5×10 6 DAN-G18.2 cell suspension (0.2 mL / cell), i.e., the inoculation volume is 1×10 6 8 days after tumor cell inoculation, the mice were treated with tumors with a volume of 65.00 to 102.85 mm 3 The mice were divided into 6 groups, including vehicle group, Comb PG Ab group (combination of Zmab-PG, H9-PG, and A6-PG antibodies), 8B CAR-T group alone, 8B CAR-T+Zmab-PG (1 mg / kg) group, 8B CAR-T+H9-PG (1 mg / kg) group, and 8B CAR-T+A6-PG (0.1 mg / kg) group, with 7 mice in each group. 8B CAR-T cells were resuspended in 1× PBS to prepare 8B CAR+ cells at 2.5×10 7 CAR was injected into the tail vein at a rate of 0.2 mL per mouse. + Cells 5×10 6 The antibody was administered intraperitoneally one day after CAR-T cell infusion, which was nine days after tumor cell inoculation. Dosing was repeated once a week and then again every two weeks. Mouse body weight and the maximum longitudinal axis (L) and maximum width (W) of the tumor tissue were monitored twice weekly.

[0220] Figure 5A shows the therapeutic effect of HuR968B CAR-T cells combined with multiple doses of P329G antibody in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells. The results showed that multiple doses of P329G (Zmab, H9, or A6) antibody induced a more sustained anti-tumor effect. The results also showed that after stopping the administration of P329G antibody, the concentration of P329G antibody in the mice gradually decreased over time, and the effect of CAR-T cells also began to weaken.

[0221] Figure 5B shows the weight changes of mice in this experiment. The results show that although the weight of mice in each treatment group fluctuated during treatment, there was no significant change compared with the control-treated mice, indicating that the combination of HuR968B CAR-T cells and multiple doses of P329G antibody did not induce significant toxicity.

[0222] Example 6: Study on the anti-tumor effect of HuR968B CAR-T cells combined with HB37A6 PG antibody at different administration orders in vivo

[0223] Mouse tumor inoculation and treatment were performed. DAN-G18.2 cells were resuspended in 1× PBS to a cell concentration of 5×10 6 NOG mice were shaved on the right side of their backs and injected subcutaneously with 5×10 6 The injection volume of DAN-G18.2 cell suspension was 0.2 mL per cell, i.e. the inoculum size was 1×10 6 Six days after tumor cell inoculation, the tumor volume of the mice ranged from 62.05 to 122.04 mm 3 The mice were divided into 6 groups, including vehicle group, 8B CAR-T group only, 8B CAR-T+A6-PG (0.03 mg / kg) group, 8B CAR-T+A6-PG (0.1 mg / kg) group, A6-PG (0.03 mg / kg)+8B CAR-T group and A6-PG (0.1 mg / kg)+8B CAR-T group, with 7 mice in each group. On the 7th day after tumor cell inoculation, 8B CAR-T cells were resuspended in 1×PBS to prepare 8B CAR+ cells at 2.5×10 7Mice in the 8BCAR-T+A6-PG (0.03 mg / kg) and 8B CAR-T+A6-PG (0.1 mg / kg) groups were injected with 0.2 mL of cell suspension per mouse via the tail vein. Mice in the A6-PG (0.03 mg / kg)+8B CAR-T and A6-PG (0.1 mg / kg)+8B CAR-T groups were administered with antibodies at doses of 0.03 mg / kg and 0.1 mg / kg, respectively, by intraperitoneal injection. On day 8 after tumor cell inoculation, mice in the 8BCAR-T+A6-PG (0.03 mg / kg) and 8BCAR-T+A6-PG (0.1 mg / kg) groups were given the antibody by intraperitoneal injection. Mice in the A6-PG (0.03 mg / kg)+8BCAR-T and A6-PG (0.1 mg / kg)+8BCAR-T groups were injected with 0.2 mL of the cell suspension per mouse via the tail vein. Mouse body weight and the maximum longitudinal axis (L) and maximum width (W) of tumor tissue were monitored twice weekly.

[0224] Figures 6A and 6B show the anti-tumor effects of different HuR968B CAR-T cell and P329G A6 antibody administration sequences in immunodeficient tumor-bearing mice inoculated with human DAN-G18.2 tumor cells. The results showed that whether the CAR-T cells or the P329G antibody were administered first did not affect the final anti-tumor effect, and the two different dosing schedules induced similar anti-tumor effects: at the 0.03mk / kg dose group, the maximum TGI for the CAR-T cell and antibody administration groups was 70.4% and 75.4%, respectively; at the 0.1mk / kg dose group, the maximum TGI for the CAR-T cell and antibody administration groups was 86.4% and 76.7%, respectively.

[0225] Based on the above Examples 1-6, the formulation formulations corresponding to the Hu968B CAR-T cell portion and the anti-Claudin18.2 antibody portion of the CAR-T cell drug (i.e., anti-claudin 18.2 (Claudin18.2) chimeric antigen receptor T cells) were screened and optimized, and formulation formulations that are beneficial to CAR-T cell stabilization (see Example 7 for details) and formulation formulations that are beneficial to antibody stabilization (see Example 8 for details) were screened out, respectively.

[0226] Example 7. Screening and Optimization of HuR968B CAR-T Cell Preparation Prescription

[0227]

Abbreviation

[0228] The abbreviations and full names involved in this embodiment are shown in Table 1 below

[0229] Table 1 Abbreviations and full names

[0230]

Experimental samples

[0231] The test samples used in this study were produced by Innovent Biologics (Suzhou) Co., Ltd. For detailed information, see Table 2.

[0232] Table 2 Information of test products used in research

[0233] Note: “ / ” means no detection.

[0234]

Other key information

[0235] Table 3 Reagents and consumables for research

[0236] Note: “N / A” means not applicable.

[0237] The main components of Bomeili A (Compound Electrolyte Injection) in Table 3 are as follows: per 1000 mL: sodium chloride 5.26g; sodium gluconate 5.02g; sodium acetate trihydrate (C2H3NaO2·3H2O) 3.68g; potassium chloride 0.37g; magnesium chloride hexahydrate (MgCl2·6H2O) 0.30g. Excipient: appropriate amount of sodium hydroxide (for pH adjustment).

[0238]

Instruments and Equipment

[0239] Table 4 Information on key instruments and equipment used in research

[0240] 7.1 Prescription Study (Material Ratio)

[0241] 7.1.1 Experimental steps

[0242] This experiment mainly investigated the CS10( The effects of different ratios of CS10), Bomeili A (compound electrolyte injection), and human serum albumin (HSA) on the stability of HuR968B CAR-T cells were studied to obtain an optimal mixing ratio range.

[0243] The experimental factors and levels are shown in Table 5. A three-factor, two-level experiment was designed using JMP15 software. A total of 12 cryopreservation solutions were prepared (see Table 6 for specific groupings). HuR968B CAR-T cells were centrifuged and resuspended in the cryopreservation solutions described above at different mixing ratios. The cell concentrations were adjusted to 1E6 cells / mL and 1E8 cells / mL and transferred to 1.8 mL cryovials. The CAR-T cell preparations were frozen using a programmed cooling device and, after the cooling process, transferred to a liquid nitrogen tank for vapor phase storage. After freezing for a period of 4 weeks, the samples were subjected to stability testing at room temperature (0, 1, 2, 4, and 8 hours). The specific experimental plan is shown in Table 6.

[0244] Table 5 Factors and levels of experimental research on HuR968B CAR-T cell preparations

[0245] Table 6 Experimental plan

[0246] Note: “●” indicates items to be tested.

[0247] 7.1.2 Experimental Results

[0248] (1) Cell viability

[0249] After four weeks of storage in liquid nitrogen vapor phase, cell viability within two hours of cell recovery was >70% for all 12 formulations at a cell density of 1E6 cells / mL. Viability at a freezing density of 1E8 cells / mL was slightly lower than that of the 1E6 cells / mL group. Cell viability in the experimental groups decreased with prolonged storage at room temperature (see Table 7 for detailed results).

[0250] Table 7 Cell viability after 4 weeks of cryopreservation

[0251] (2) Cell clumping rate

[0252] After 4 weeks of storage under vapor phase liquid nitrogen conditions, the cell agglomeration rates of the 12 formulation groups did not change significantly, and storage at room temperature for different periods of time did not affect the cell agglomeration rates (see Table 8 for specific results).

[0253] Table 8 Cell agglomeration rate after 4 weeks of cryopreservation

[0254] (3)CD3 + CAR + and T cell phenotype

[0255] After 4 weeks of storage under liquid nitrogen, CD3 + CAR + , T cell phenotype (specifically including TE 、T N 、T CM and T EM ) There was no obvious trend of change. + The detection values ​​of CAR were more dispersed (21.40% to 31.70%), and the CAR of 1E8 / mL cell density group was + The detection values ​​of group T were more concentrated (23.0% to 28.7%); group T N The detection values ​​of the group T were more concentrated and the overall values ​​were higher (48.2% to 57.2%). N The detection values ​​were generally low (42.3% to 55.0%) (see Table 9 for specific results).

[0256] Table 9 CAR positive rate and T cell phenotype after 4 weeks of cryopreservation

[0257] Note: “*” indicates abnormal data and is discarded.

[0258] In summary, the results of the formulation research experiments showed that under the same preparation freezing conditions, the viability after resuscitation of the 12 experimental groups with a cell density of 1E8 cells / mL was lower than that of the cell density of 1E6 cells / mL. Therefore, in the formulation confirmation experiment, the worst case scenario (1E8 cells / mL) was used for formulation confirmation.

[0259] 7.2 Prescription Confirmation

[0260] 7.2.1 Experimental steps

[0261] For the configuration of the 12 groups of preparation prescriptions, test time points, and test items, please refer to the "7.1.1 Experimental Procedures" section of this example.

[0262] 7.2.2 Experimental Results

[0263] (1) Cell viability

[0264] After 4 weeks of storage under vapor phase liquid nitrogen conditions, the cell viability of the 12 formulations after cell recovery was >70%. As the storage time at room temperature increased, the cell viability of all groups decreased (see Table 10 for details).

[0265] Table 10 Cell viability after 4 weeks of cryopreservation

[0266] (2) Agglomeration rate

[0267] After 4 weeks of storage under vapor phase liquid nitrogen conditions, the cell agglomeration rates of the 12 formulation groups did not change significantly, and storage at room temperature for different periods of time did not affect the cell agglomeration rates (see Table 11 for details).

[0268] Table 11 Cell agglomeration rate after 4 weeks of cryopreservation

[0269] (3)CD3 + CAR + and T cell phenotype

[0270] After 4 weeks of storage under liquid nitrogen, CD3 + CAR + , T cell phenotype (including T E 、T N 、T CM and T EM ) showed no obvious trend of change (see Table 12 for details).

[0271] Table 12 CAR positive rate and T cell phenotype after 4 weeks of cryopreservation

[0272] (4) Result analysis

[0273] 1. The cell viability data from the prescription validation experiment (1E8 cells / mL) at 0, 1, 2, 4, and 8 hours after resuscitation, four weeks after resuscitation, were entered into the JMP15 data table and fitted using the least squares method. Figures 7 and 11 show that the P values ​​for "viability 0 hour" and "viability 8 hours" were > 0.05, indicating that the model was not significant. Figures 8, 9, and 10 show that the P values ​​for "viability 1 hour," "viability 2 hours," and "viability 4 hours" were 0.0003, 0.0016, and 0.0004, respectively, all < 0.05, indicating that the model was significant.

[0274] 2. Knowing that in actual use, CAR-T cells are typically revived and infused within 2 hours, the predictive profiler sets the importance of "1-hour" and "2-hour" to 1, and "4-hour" to 0.1. Because the models for "0-hour" and "8-hour" are not significant, their importance is set to 0. The optimal conditions, derived from the desirability function, are CS10 50.0%, BP A 30.5%, and HSA 19.5%, as shown in Figure 12.

[0275] 7.2.3 Test conclusion

[0276] Based on the above experimental results and the platform experience in formulation development, the stable formulation of Hu968B CAR-T cells was finally selected, which consists of: 1E6 cells / mL to 1E8 cells / mL Hu968B CAR-T cells, CS10 50%-70% (v / v), Bolili A compound electrolyte injection 10.5%-50.5% (v / v), human serum albumin 14.5%-24.5% (v / v).

[0277] Based on these studies, the optimal formulation for the chimeric antigen receptor T cell component of a recombinant anti-claudin 18.2 monoclonal antibody preparation and a chimeric antigen receptor T cell preparation (drug combination) was determined. In practice, the chimeric antigen receptor T cell preparation is packaged in 40 mL / bags, in the form of an injection, and administered intravenously.

[0278] Example 8: Screening and Optimization of HB37A6 PG Antibody Formulation

[0279]

Abbreviation

[0280] The abbreviations and full names involved in this embodiment are shown in Table 13 below

[0281] Table 13 Abbreviations and full names

[0282]

Experimental samples

[0283] The test samples used in this study were produced by Innovent Biologics (Suzhou) Co., Ltd. For detailed information, see Table 14.

[0284] Table 14 Sample information

[0285]

Other key information

[0286] See Table 15 and Table 16 for detailed information:

[0287] Table 15 Reagent information

[0288] Note: N / A means not applicable.

[0289] Table 16 Material information

[0290]

Instruments and Equipment

[0291] See Table 17 for detailed information.

[0292] Table 17 Instrument and equipment information

[0293] 8.1 Experimental steps

[0294] Based on the experience of the formulation development platform, a total of four formulations were designed. Detailed formulation information is shown in Table 18. The buffer solution for each formulation was prepared, and the HB37A6 antibody protein was ultrafiltered and replaced into the respective formulation solution using a desktop refrigerated centrifuge. After ultrafiltration and replacement, the protein concentration of each formulation was diluted to approximately 10 mg / ml, and polysorbate 80 was added. The solution was filtered and dispensed into vials, stoppered, and capped. High-temperature forced testing, accelerated testing, long-term testing, oscillation, freeze-thaw, and light stability tests were performed. Testing items included appearance, antibody protein content (UV method), pH value, polysorbate 80 content, purity (SEC-HPLC method and non-reduced CE-SDS method), charge variants (iCIEF method), and biological activity (ELISA method).

[0295] Table 18 Prescription Information

[0296] Detailed experimental conditions and sampling plan are shown in Table 19.

[0297] Table 19 Stability investigation plan

[0298] 8.2 Judgment criteria

[0299] Based on the understanding of the product and the precision of the instruments and methods, a judgment standard was set to determine whether the quality of the sample test value has not changed compared with the initial value, which is used to determine whether the sample has changed. See Table 20 for details.

[0300] Table 20 Criteria for judging if quality has not changed

[0301] 8.3 Experimental Results

[0302] The results of the prescription screening study are detailed in Tables 21 to 26, the purity change trend is shown in Figure 13, and the change trend of different components of charge variants at different temperatures (iCIEF method) is shown in Figures 14 to 17.

[0303] The results showed that: (1) After being placed at 40℃±2℃ for 4 weeks, the appearance and biological activity (ELISA method) of each formulation were qualified; the antibody protein content, pH value and purity (SEC-HPLC method) of each formulation did not change significantly; the purity (non-reduced CE-SDS method) of each formulation showed a downward trend, among which the change range of formulation 4 was relatively slow; the acidic components of the charge variants (iCIEF method) of each formulation increased significantly, the main components decreased significantly, and the alkaline components did not change significantly, among which the change range of formulations 3 and 4 was relatively slow (see Table 21 for details). (2) After being placed at 25℃±2℃ for 2 months, the appearance and biological activity (ELISA method) of each formulation were qualified; the antibody protein content, pH value and purity (SEC-HPLC method and non-reduced CE-SDS method) of each formulation did not change significantly; the acidic components of the charge variants (iCIEF method) of each formulation increased significantly, the main components decreased significantly, and the alkaline components did not change significantly, among which the change range of formulations 3 and 4 was relatively slow (see Table 22 for details). (3) After being placed at 5℃±3℃ for 2 months (see Table 23 for details), shaken (650 rpm, room temperature, protected from light) for 3 days (see Table 24 for details), frozen and thawed 6 times (see Table 25 for details), and exposed to light (25℃±2℃, 500Lux±50Lux) for 5 days, no significant changes were observed in the test indicators (see Table 26 for details).

[0304] Table 21 Prescription screening study results (40°C)

[0305] Table 22 Prescription screening study results (25℃)

[0306] Table 23 Prescription screening study results (2~8℃)

[0307] Table 24 Prescription screening study results (oscillation)

[0308] Table 25 Prescription screening study results (freeze-thaw)

[0309] Table 26 Prescription screening study results (light exposure)

[0310] 8.4 Experimental Conclusion

[0311] Based on the above experimental results and the platform experience in formulation formulation development, formulation 4 was finally selected as the stable formulation formulation of HB37A6 antibody, whose composition is: 10.0 mg / ml recombinant anti-tight junction protein 18.2 (Claudin 18.2) monoclonal antibody HB34A6, 0.53 mg / ml histidine, 1.38 mg / ml histidine hydrochloride, 29.00 mg / ml sorbitol, 10.53 mg / ml arginine hydrochloride, 0.01 mg / ml disodium edetate, 0.5 mg / ml polysorbate 80, pH 5.8.

[0312] Based on these studies, the optimal formulation for the recombinant anti-claudin 18.2 monoclonal antibody component of the recombinant anti-claudin 18.2 monoclonal antibody preparation and chimeric antigen receptor T cell preparation (drug combination) was determined. In practice, the finished antibody preparation is available in a 100 mg (10 mL) vial, in the form of an injection, and is administered intravenously.

[0313] It should be noted that, although the technical solutions of the present invention are described with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.

[0314] While various embodiments of the present invention have been described above, the above descriptions are intended to be illustrative, non-exhaustive, and not limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terminology used herein is selected to best explain the principles of the embodiments, their practical applications, or technological improvements in the marketplace, or to enable others skilled in the art to understand the embodiments disclosed herein.

[0315] Sequence Listing

Claims

1. A pharmaceutical combination preparation, comprising preparation A and preparation B; in, The preparation A comprises: a therapeutically effective amount of immune effector cells expressing a molecular switch-regulated chimeric antigen receptor (CAR) polypeptide and a pharmaceutical excipient I, The pharmaceutical excipient I comprises: compound electrolyte injection, human serum albumin and CS10; Preferably, the compound electrolyte injection is Bomel A compound electrolyte injection; The preparation B comprises: a therapeutically effective amount of an antibody or antigen-binding fragment comprising a P329G mutation that specifically binds to the CLDN18.2 molecule and a pharmaceutical excipient II, The P329G mutated antibody that specifically binds to the CLDN18.2 molecule comprises a mutated Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G), and the Fcγ receptor binding of the mutated Fc domain is reduced compared to the Fcγ receptor binding of the unmutated parent antibody Fc domain; The pharmaceutical excipient II comprises: a pH regulator, an osmotic pressure regulator, a metal chelating agent and a surfactant; Preferably, the pH regulator is histidine and / or histidine hydrochloride, the osmotic pressure regulator is arginine hydrochloride and / or sorbitol, the surfactant is polysorbate 80, and the metal chelator is disodium edetate.

2. The pharmaceutical combination preparation according to claim 1, characterized in that: Wherein the molecular switch regulated chimeric antigen receptor (CAR) polypeptide comprises: (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that can specifically bind to the Fc domain of an antibody comprising the P329G mutation, but cannot specifically bind to the Fc domain of an unmutated parent antibody: (i) a heavy chain variable region comprising a (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 13); (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 14); and (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 15); and (ii) a light chain variable region comprising a (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 16); (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 17); and (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 18); Preferably, the (i) heavy chain variable region comprises the sequence of SEQ ID NO: 2, and (ii) light chain variable region comprises the sequence of SEQ ID NO: 3; (2) a hinge region / spacer region selected from the sequence shown in SEQ ID NO: 4 or SEQ ID NO: 5; (3) a transmembrane region (TM), which is the CD8 transmembrane domain shown in SEQ ID NO: 6; (4) a costimulatory signaling domain (CSD), which is the 4-1BB costimulatory domain shown in SEQ ID NO: 7; (5) a stimulatory signaling domain (SSD), which is the CD3ζ signaling domain shown in SEQ ID NO: 8; (6) a signal peptide sequence, which is the signal peptide sequence shown in SEQ ID NO: 1; Preferably, the molecular switch-regulated CAR polypeptide has an amino acid sequence as shown in SEQ ID NO: 9, and the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide comprises a nucleotide sequence as shown in SEQ ID NO: 10; The immune effector cells expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide are T cells; preferably, the T cells are autologous T cells or allogeneic T cells; more preferably, the immune effector cells are prepared by isolating T cells from human PBMCs; Most preferably, the immune effector cell expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide is a HuR968B CAR-T cell.

3. The pharmaceutical combination preparation according to claim 1 or 2, characterized in that: The cell density of the immune effector cells expressing the molecular switch-regulated chimeric antigen receptor (CAR) polypeptide in the preparation A is 1E6 cells / mL to 1E8 cells / mL; The contents of the components in the pharmaceutical excipient I in the preparation A are: compound electrolyte injection 10.5% to 50.5% (v / v), human serum albumin 14.5 to 24.5% (v / v), CS10 50%~70% (v / v); Preferably, the contents of the components in the pharmaceutical excipient I in the preparation A are respectively CS10 50.0% (v / v), compound electrolyte injection 30.5% (v / v), human serum albumin 19.5%; More preferably, the compound electrolyte injection is Bomel A compound electrolyte injection.

4. The pharmaceutical combination preparation according to any one of claims 1 to 3, characterized in that wherein the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 shown in the amino acid sequence SYVMS (SEQ ID NO: 19) according to Kabat numbering; a CDR H2 shown in the amino acid sequence TISHSGGSTYYADSVKG (SEQ ID NO: 20); and a CDR H3 shown in the amino acid sequence DAPYYDILTGYRY (SEQ ID NO: 21); the light chain variable region comprises a CDR L1 shown in the amino acid sequence RASQSISSWLA (SEQ ID NO: 22) according to Kabat numbering, a CDR L2 shown in the amino acid sequence KASSLES (SEQ ID NO: 23); and a CDR L3 shown in the amino acid sequence QQYNSYSYT (SEQ ID NO: 24); Preferably, the heavy chain variable region comprises the sequence of SEQ ID NO: 11, and the light chain variable region comprises the sequence of SEQ ID NO: 12 wherein the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody; Most preferably, the P329G mutated antibody that specifically binds to the CLDN18.2 molecule is HB37A6 PG Ab.

5. The pharmaceutical combination preparation according to any one of claims 1 to 4, characterized in that: The content of the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule and contains the P329G mutation in the preparation B is 8 to 12 mg / mL; preferably, the content of the antibody or antigen-binding fragment that specifically binds to the CLDN18.2 molecule and contains the P329G mutation in the preparation B is 10.0 mg / mL; The contents of the components in the pharmaceutical excipient II in the preparation B are: 5-20 mM pH regulator, 30-50 mg / mL osmotic pressure regulator, 0.005-0.02 mg / mL metal chelator and 0.3-0.7 mg / mL surfactant; Preferably, the contents of the components in the pharmaceutical excipient II in the preparation B are: 10 mM pH regulator, 39.53 mg / mL osmotic pressure regulator, 0.01 mg / mL metal chelator and 0.5 mg / mL surfactant; More preferably, the contents of the components in the pharmaceutical excipient II in the preparation B are: 0.53 g / ml histidine, 1.38 mg / mL histidine hydrochloride, 29.00 mg / mL sorbitol, 10.53 mg / mL arginine hydrochloride, 0.01 mg / mL edetate disodium, 0.5 mg / mL polysorbate 80; Optionally, the pH of Formulation B is 5.

8.

6. The pharmaceutical combination preparation according to any one of claims 1 to 5, wherein the preparation A and preparation B are administered separately, simultaneously or sequentially.

7. The pharmaceutical combination preparation according to claim 6, wherein the administration method is parenteral administration; preferably, the administration method is intravenous administration.

8. Use of the pharmaceutical combination preparation according to any one of claims 1 to 7 in the preparation of a medicament for treating and / or preventing cancer; preferably, the cancer is a cancer that expresses or overexpresses CLDN 18.2; more preferably, the cancer is a CLDN18.2-positive solid tumor.

9. A method for treating and / or preventing cancer, the method comprising administering to a subject in need thereof the pharmaceutical combination preparation of any one of claims 1 to 7; preferably, the cancer is a cancer that expresses or overexpresses CLDN 18.2; more preferably, the cancer is a CLDN18.2-positive solid tumor.

10. The method according to claim 9, wherein the administration is parenteral administration; preferably, the administration is intravenous administration.

Citation Information

Patent Citations

  • Pharmaceutical formulations comprising bispecific antibodies against

    CN114748618A

  • Immune-activated Fc domain binding molecules

    CN115916827A

  • CD79b chimeric antigen receptors

    US20220226374A1

  • Methods and compositions for modulating car-t activity

    US20220227865A1

  • Compositions and methods for the treatment of cancer using next generation engineered t cell therapy

    WO2022093884A1